[{"orgOrder":0,"company":"Heron Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Granisetron","moa":"Serotonin 3a (5-HT3a) receptor","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Heron Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous","sponsorNew":"Heron Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Heron Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Cumberland Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Granisetron","moa":"Serotonin 3a (5-HT3a) receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Kyowa Kirin","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Kyowa Kirin \/ Cumberland Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Kyowa Kirin \/ Cumberland Pharmaceuticals"},{"orgOrder":0,"company":"Cumberland Pharmaceuticals","sponsor":"Verity Pharmaceuticals Inc","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Granisetron","moa":"Serotonin 3a (5-HT3a) receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Cumberland Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Cumberland Pharmaceuticals \/ Verity Pharmaceuticals Inc","highestDevelopmentStatusID":"15","companyTruncated":"Cumberland Pharmaceuticals \/ Verity Pharmaceuticals Inc"},{"orgOrder":0,"company":"Indiana University","sponsor":"Kyowa Kirin","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Granisetron","moa":"Serotonin 3a (5-HT3a) receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Indiana University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Indiana University \/ Kyowa Kirin","highestDevelopmentStatusID":"8","companyTruncated":"Indiana University \/ Kyowa Kirin"},{"orgOrder":0,"company":"Solasia Pharma KK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Granisetron","moa":"Serotonin 3a (5-HT3a) receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Solasia Pharma KK","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Solasia Pharma KK \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Solasia Pharma KK \/ Inapplicable"},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"PPD","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Granisetron","moa":"Serotonin 3a (5-HT3a) receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Kyowa Kirin","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Patch","sponsorNew":"Kyowa Kirin \/ PPD","highestDevelopmentStatusID":"6","companyTruncated":"Kyowa Kirin \/ PPD"}]

Find Clinical Drug Pipeline Developments & Deals for Kytril

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          CPhI Korea
                          Not Confirmed
                          CPhI Korea
                          Not Confirmed

                          Details : Under the terms of that agreement, Cumberland acquired U.S. rights to Sancuso (Granisetron) and assumed full commercial responsibility for the product – including its distribution, marketing, promotion, manufacturing and medical support activities.

                          Product Name : Sancuso

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          September 05, 2022

                          Lead Product(s) : Granisetron

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Approved FDF

                          Sponsor : Verity Pharmaceuticals Inc

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          02

                          CPhI Korea
                          Not Confirmed
                          CPhI Korea
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Sustol

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          June 28, 2022

                          Lead Product(s) : Granisetron

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Phase IV

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          CPhI Korea
                          Not Confirmed
                          CPhI Korea
                          Not Confirmed

                          Details : Under the terms of the agreement, Cumberland will acquire U.S. rights to SANCUSO (Granisetron) and will assume full commercial responsibility for the product - including its marketing, promotion, distribution, manufacturing and medical support activities...

                          Product Name : Sancuso

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          April 01, 2022

                          Lead Product(s) : Granisetron

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Approved FDF

                          Sponsor : Cumberland Pharmaceuticals

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          blank

                          04

                          CPhI Korea
                          Not Confirmed
                          CPhI Korea
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          October 13, 2021

                          Lead Product(s) : Granisetron

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          CPhI Korea
                          Not Confirmed
                          CPhI Korea
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          August 30, 2021

                          Lead Product(s) : Granisetron

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I

                          Sponsor : PPD

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          Indiana University

                          Country arrow
                          CPhI Korea
                          Not Confirmed

                          Indiana University

                          Country arrow
                          CPhI Korea
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          August 06, 2020

                          Lead Product(s) : Granisetron

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Phase II

                          Sponsor : Kyowa Kirin

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          University of Alabama at Birmingham

                          Country arrow
                          CPhI Korea
                          Not Confirmed

                          University of Alabama at Birmingham

                          Country arrow
                          CPhI Korea
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          September 11, 2019

                          Lead Product(s) : Granisetron

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Phase II

                          Sponsor : Heron Therapeutics

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          Maxinase Life Sciences

                          Country arrow
                          CPhI Korea
                          Not Confirmed

                          Maxinase Life Sciences

                          Country arrow
                          CPhI Korea
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          September 30, 2015

                          Lead Product(s) : Granisetron

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Tri-Service General Hospital

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          CPhI Korea
                          Not Confirmed
                          CPhI Korea
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          April 08, 2014

                          Lead Product(s) : Granisetron

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          Duke University

                          Country arrow
                          CPhI Korea
                          Not Confirmed

                          Duke University

                          Country arrow
                          CPhI Korea
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          September 30, 2013

                          Lead Product(s) : Granisetron

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Kyowa Kirin

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank